Bracco Diagnostics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization
Phase 3
Completed
- Conditions
- Liver Neoplasms
- Interventions
- Drug: SonoVue-enhanced ultrasoundOther: Unenhanced ultrasound
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 349
- Registration Number
- NCT00788697
- Locations
- 🇺🇸
Bracco Diagnostics Inc, Princeton, New Jersey, United States
Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients
Phase 4
Terminated
- Conditions
- Chronic Renal ImpairmentDiabetes Mellitus
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 23
- Registration Number
- NCT00782639
- Locations
- 🇺🇸
Bracco Diagnostics Inc., Princeton, New Jersey, United States
Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)
Completed
- Conditions
- Renal Insufficiency
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2012-09-18
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 405
- Registration Number
- NCT00773409
- Locations
- 🇺🇸
Bracco Diagnostics Inc., Princeton, New Jersey, United States
Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral DSA
Phase 4
Completed
- Conditions
- Peripheral Arterial Occlusive Disease
- Interventions
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 33
- Registration Number
- NCT00740207
Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease
Completed
- Conditions
- Renal Insufficiency
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 366
- Registration Number
- NCT00600951
- Locations
- 🇺🇸
Bracco Diagnostics Inc., Princeton, New Jersey, United States
Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease
Completed
- Conditions
- Renal Insufficiency
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 172
- Registration Number
- NCT00600834
- Locations
- 🇺🇸
Bracco Diagnostic Inc., Princeton, New Jersey, United States
Coronary MDCTA With Iopamidol Injection 370
Phase 2
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: Isovue 370, 70 mLDrug: Isovue 370, 80 mLDrug: Isovue 370, 90 mL
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2012-10-24
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 210
- Registration Number
- NCT00558792
- Locations
- 🇺🇸
Bracco Diagnostics, Princeton, New Jersey, United States
Multihance Versus Magnevist in Breast MRI
Phase 3
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2010-07-15
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 130
- Registration Number
- NCT00486473
Follow-up Study to Previous CARE Trial
Completed
- Conditions
- Moderate to Severe Chronic Kidney Disease
- Interventions
- Drug: iodinated contrast agent
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2009-09-30
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 294
- Registration Number
- NCT00479024
- Locations
- 🇺🇸
Cardiovascular Associates, Birmingham, Alabama, United States
Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 39
- Registration Number
- NCT00415805
- Locations
- 🇮🇹
Bracco Imaging, S.p.A, Milan, Italy
© Copyright 2025. All Rights Reserved by MedPath